283 related articles for article (PubMed ID: 23163725)
1. Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features.
Matsubara D; Kishaba Y; Ishikawa S; Sakatani T; Oguni S; Tamura T; Hoshino H; Sugiyama Y; Endo S; Murakami Y; Aburatani H; Fukayama M; Niki T
Cancer Sci; 2013 Feb; 104(2):266-73. PubMed ID: 23163725
[TBL] [Abstract][Full Text] [Related]
2. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
[TBL] [Abstract][Full Text] [Related]
3. Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma.
Song S; Nguyen V; Schrank T; Mulvaney K; Walter V; Wei D; Orvis T; Desai N; Zhang J; Hayes DN; Zheng Y; Major MB; Weissman BE
Mol Cancer Res; 2020 Dec; 18(12):1777-1788. PubMed ID: 32855269
[TBL] [Abstract][Full Text] [Related]
4. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
5. Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma.
Endo M; Yasui K; Zen Y; Gen Y; Zen K; Tsuji K; Dohi O; Mitsuyoshi H; Tanaka S; Taniwaki M; Nakanuma Y; Arii S; Yoshikawa T
Liver Int; 2013 Jan; 33(1):105-17. PubMed ID: 23088494
[TBL] [Abstract][Full Text] [Related]
6. SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature.
Nambirajan A; Singh V; Bhardwaj N; Mittal S; Kumar S; Jain D
Arch Pathol Lab Med; 2021 Jan; 145(1):90-98. PubMed ID: 33367658
[TBL] [Abstract][Full Text] [Related]
7. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis.
Reisman DN; Sciarrotta J; Wang W; Funkhouser WK; Weissman BE
Cancer Res; 2003 Feb; 63(3):560-6. PubMed ID: 12566296
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers.
Sun A; Tawfik O; Gayed B; Thrasher JB; Hoestje S; Li C; Li B
Prostate; 2007 Feb; 67(2):203-13. PubMed ID: 17075831
[TBL] [Abstract][Full Text] [Related]
9. BRG1 loss in MiaPaCa2 cells induces an altered cellular morphology and disruption in the organization of the actin cytoskeleton.
Rosson GB; Bartlett C; Reed W; Weissman BE
J Cell Physiol; 2005 Nov; 205(2):286-94. PubMed ID: 15887247
[TBL] [Abstract][Full Text] [Related]
10. Co-regulation of transcription by BRG1 and BRM, two mutually exclusive SWI/SNF ATPase subunits.
Raab JR; Runge JS; Spear CC; Magnuson T
Epigenetics Chromatin; 2017 Dec; 10(1):62. PubMed ID: 29273066
[TBL] [Abstract][Full Text] [Related]
11. Targeting of BRM Sensitizes
Zernickel E; Sak A; Riaz A; Klein D; Groneberg M; Stuschke M
Mol Cancer Ther; 2019 Mar; 18(3):656-666. PubMed ID: 30478150
[TBL] [Abstract][Full Text] [Related]
12. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.
Hoffman GR; Rahal R; Buxton F; Xiang K; McAllister G; Frias E; Bagdasarian L; Huber J; Lindeman A; Chen D; Romero R; Ramadan N; Phadke T; Haas K; Jaskelioff M; Wilson BG; Meyer MJ; Saenz-Vash V; Zhai H; Myer VE; Porter JA; Keen N; McLaughlin ME; Mickanin C; Roberts CW; Stegmeier F; Jagani Z
Proc Natl Acad Sci U S A; 2014 Feb; 111(8):3128-33. PubMed ID: 24520176
[TBL] [Abstract][Full Text] [Related]
13. SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation.
Banine F; Bartlett C; Gunawardena R; Muchardt C; Yaniv M; Knudsen ES; Weissman BE; Sherman LS
Cancer Res; 2005 May; 65(9):3542-7. PubMed ID: 15867346
[TBL] [Abstract][Full Text] [Related]
14. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.
Glaros S; Cirrincione GM; Muchardt C; Kleer CG; Michael CW; Reisman D
Oncogene; 2007 Oct; 26(49):7058-66. PubMed ID: 17546055
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers.
Papillon JPN; Nakajima K; Adair CD; Hempel J; Jouk AO; Karki RG; Mathieu S; Möbitz H; Ntaganda R; Smith T; Visser M; Hill SE; Hurtado FK; Chenail G; Bhang HC; Bric A; Xiang K; Bushold G; Gilbert T; Vattay A; Dooley J; Costa EA; Park I; Li A; Farley D; Lounkine E; Yue QK; Xie X; Zhu X; Kulathila R; King D; Hu T; Vulic K; Cantwell J; Luu C; Jagani Z
J Med Chem; 2018 Nov; 61(22):10155-10172. PubMed ID: 30339381
[TBL] [Abstract][Full Text] [Related]
16. Combined gene dosage requirement for SWI/SNF catalytic subunits during early mammalian development.
Smith-Roe SL; Bultman SJ
Mamm Genome; 2013 Feb; 24(1-2):21-9. PubMed ID: 23076393
[TBL] [Abstract][Full Text] [Related]
17. Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia.
Rago F; Rodrigues LU; Bonney M; Sprouffske K; Kurth E; Elliott G; Ambrose J; Aspesi P; Oborski J; Chen JT; McDonald ER; Mapa FA; Ruddy DA; Kauffmann A; Abrams T; Bhang HC; Jagani Z
Mol Cancer Res; 2022 Mar; 20(3):361-372. PubMed ID: 34799403
[TBL] [Abstract][Full Text] [Related]
18. Functional redundancy of SWI/SNF catalytic subunits in maintaining vascular endothelial cells in the adult heart.
Willis MS; Homeister JW; Rosson GB; Annayev Y; Holley D; Holly SP; Madden VJ; Godfrey V; Parise LV; Bultman SJ
Circ Res; 2012 Aug; 111(5):e111-22. PubMed ID: 22740088
[TBL] [Abstract][Full Text] [Related]
19. BRG1 and BRM function antagonistically with c-MYC in adult cardiomyocytes to regulate conduction and contractility.
Willis MS; Holley DW; Wang Z; Chen X; Quintana M; Jensen BC; Tannu M; Parker J; Jeyaraj D; Jain MK; Wolfram JA; Lee HG; Bultman SJ
J Mol Cell Cardiol; 2017 Apr; 105():99-109. PubMed ID: 28232072
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype.
Kim H; Jang SJ; Chung DH; Yoo SB; Sun P; Jin Y; Nam KH; Paik JH; Chung JH
PLoS One; 2013; 8(10):e76999. PubMed ID: 24194854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
